At a glance
- Originator Rottapharm
- Developer Rottapharm Madaus
- Class Anti-inflammatories; Benzamidines; Small molecules
- Mechanism of Action Metalloprotease inhibitors; Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diarrhoea; Inflammatory bowel diseases; Mucositis
Most Recent Events
- 22 Sep 2017 No recent reports on development identified - Phase-II for Inflammatory bowel disease, Mucositis (Chemotherapy-induced) and Diarrhoea (Chemotherapy-induced) in Italy (unspecified route)
- 01 Nov 2014 Phase II development for Diarrhoea, Inflammatory bowel disease and Mucositis is ongoing in Italy
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda